Dream Garden scrubs up for Hong Kong IPO
The fast-growing personal care products maker is hoping to beat out rivals also looking to raise cash in the hot Hong Kong stock market Key Takeaways: Dream Garden has filed…
InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Biogene gets bruised in ‘Battle of the skincare belles’
A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
Biogene gets bruised in ‘Battle of the skincare belles’
2367.HK
688363.SHG
